AbbraTech – Custom recombinant antibody discovery and development services

Recombinant antibody discovery and development

Abbratech’s technology allows us to make antibodies with a targeted precision not obtainable using any other available means.

The Technology

Our focus is on ‘precision antibodies.’ We want to be able to derive antibodies to specific sites on an antigen at a nearly amino acid resolution. Regardless of target immunogenicity, tolerance, or modification. No longer should a discovery antibody be about ‘what is a good epitope?’ It now becomes ‘where do you want the antibody to bind.’

About Us

The company was founded in 2020 in Branford, Connecticut by a team of experienced and successful life science industry researchers. The company was formed to address the current problems in the antibody development paradigm; it is too slow and does not always result in consistent, renewable, and precise antibodies. Abbratech’s EPIVOLVE^sm technology provides a comprehensive custom recombinant antibody discovery and development services platform. Our service offerings include antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Continued innovation is what we do.

How we became who we are

The name is really a double entendre. With the first meaning being an acronym made up from what we work with, and where we are located: Antibodies (Ab) Branford (bra) Technologies (tech)….Abbratech. But ‘abra,’ with only one ‘b’ in Aramaic also means ‘it is created’. Something that we feel fits in with what we do

What We Do

Antibodies are produced in the body as the part of the immune system that is able to target foreign invaders in a ‘lock and key’ mechanism. Over the years, antibodies have been used by researchers and physicians to diagnose and combat disease. Abbratech addresses the need in the research, pharmaceutical, and diagnostic markets for the isolation of affinity reagents against difficult targets.

Abbratech uses the best available in vivo and in vitro methods for antibody discovery. This includes both phage display and small animal B-cell cloning methods. Abbratech is applying knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. Abbratech’s EPIVOLVE^sm technology allows us to make antibodies with a targeted precision not obtainable using any other available means.